---
title: "INNOVENT BIO  Interim Net Profit Up 50.2% to RMB1.25B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296896551.md"
description: "INNOVENT BIOreported interim results for the six months ended June 2026, showing a 50.2% YoY increase in net profit to RMB1.253 billion and a 44.8% rise in total revenue to RMB8.618 billion. Non-IFRS profit grew 40.5% to RMB1.703 billion, while Non-IFRS EBITDA increased 47.1% to RMB2.08 billion. Gross profit reached RMB7.32 billion with an 85% margin."
datetime: "2026-08-25T10:25:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296896551.md)
  - [en](https://longbridge.com/en/news/296896551.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296896551.md)
generator: "portal-rs"
---

# INNOVENT BIO  Interim Net Profit Up 50.2% to RMB1.25B

INNOVENT BIO (01801.HK) +0.600 (+0.603%) Short selling $145.29M; Ratio 11.889% announced its interim results for the six months ended June 2026. Total revenue mounted 44.8% YoY to RMB8.618 billion. Profit for the period climbed 50.2% YoY to RMB1.253 billion. EPS was RMB0.73. Non-IFRS profit during the period grew 40.5% to RMB1.703 billion.  

During the period, gross profit lifted 43% to RMB7.32 billion, while gross margin edged down to 85% from 86%. Non-IFRS EBITDA rose 47.1% to RMB2.08 billion.  
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-25 16:25.)

AASTOCKS Financial News

### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

- [Innovent Biologics H1 FY26 IFRS profit climbs 50.2% to RMB 1.25 billion; revenue rises 44.8% to RMB 8.62 billion](https://longbridge.com/en/news/296892741.md)
- [Innovent Biologics: 2026H1 revenue and profit soared, driven by robust product growth and global expansion](https://longbridge.com/en/news/296925554.md)
- [HUM: Underlying NPAT reached AUD 44.2 million, with FY 2027 targeting productivity and 12%-14% ROE](https://longbridge.com/en/news/296853847.md)
- [Innovent Biologics signs exclusive deal with Daiichi Sankyo to commercialize Vanflyta in China](https://longbridge.com/en/news/295337735.md)
- [Innovent Biologics Shareholders Approve All AGM Resolutions, Strengthening Capital Flexibility](https://longbridge.com/en/news/290747206.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**